Business Wire

TERRANET

Share
Terranet to Present First Serious Lidar Alternative at CES

At next week’s International CES 2020, Terranet will demonstrate VoxelFlow - a 3D motion perception technology capable of detecting and classifying objects far more accurately and exponentially faster than Lidar. Terranet’s demo is timely considering Tesla CEO Elon Musk shocked the press just last April with his remarks: “Lidar is a fool’s errand. Anyone relying on Lidar is doomed. Doomed!” In a bold move, Swedish-headquartered Terranet plans on backing up Musk’s claims that Lidar is merely a dangerous shortcut to image recognition – a perilous reliance if that’s what the promised fully autonomous cars of the future will continue to use.

Invented by Dirk Smits, VoxelFlow was built upon the understanding that today’s camera-based computer vision and artificial intelligence navigation systems are simply too slow and subject to fundamental speed limits of perception using a frame based approach. Lidar has limited resolution and slow scanning rates, making it nearly impossible to distinguish between, for example, a fixed lamppost and a running child.

The underlying problem with Lidar or any existing camera/computer vision technology is that it cannot detect vulnerable road users with low latency. VoxelFlow on the other hand classifies dynamic moving objects at extremely low latency using very low computational power, producing 10 million 3D points per second, resulting in rapid edge detection without motion blur. The iPhone’s ‘selfie’ camera pales in comparison, producing a mere 33,000 light points per frame. Put into context, standard vehicles today and even those with autonomous driving roadmaps in place don’t use cameras much stronger than that of the iPhone’s selfie camera.

VoxelFlow’s capabilities are especially relevant considering harrowing statistics indicating that 80% of all crashes and 65% of all near-crashes involve driver inattention within the last 3 seconds of the crash. By providing life-saving decision making in milliseconds versus seconds, Terranet envisions transforming the pre-crash inattention that today accounts for roughly 1.35M road accident deaths into a forgotten collision-free swerve on the road.

“Terranet succeeding in proving VoxelFlow as a serious and necessary contender to Lidar is just the kind of shake-up the oft self-congratulatory autonomous driving community needs to kick start the new decade and save lives,” says Terranet CEO, Pär-Olof Johannesson.

To schedule a viewing of the VoxelFlow demo during CES, please contact Christina Björnström at +1-818-672-6954 or contact Lena Hägvall via email lena.hagvall@terranet.se
www.terranet.se
https://vimeo.com/377730923

ABOUT TERRANET

Terranet design radio and vision based ADAS software platforms for collision avoidance. Terranet is headquartered in Lund, Sweden, with offices in Stuttgart and California. Terranet Holding AB (publ) is listed on Nasdaq First North Premier.

www.terranet.se

Appointed Certified Adviser to Terranet Holding AB (publ) is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 05:00:00 CET | Press release

The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow

DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 04:00:00 CET | Press release

MoU signed at the Singapore Fintech Festival 2025 covers several areas of strategic cooperation to scale digital payments, strengthen connectivity and advance fintech innovationPartnership enables DBS PayLah! users to scan Alipay+ QR codes to pay at more than 150 million merchants across over 100 markets DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digita

LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release

LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa

VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release

Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 00:00:00 CET | Press release

Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye